JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Combined photocoagulation and cryotherapy in treatment of Eales' retinopathy. Preliminary report.

This is a preliminary report of Eales' disease study (EDS). Compilation of two years data shows that combined xenon are photocoagulation and peripheral cryotherapy has beneficial effects in treatment of Eales' disease with grade II and grade III retinopathy. In very advanced stage of the disease (grade IV retinopathy) the treatment has no beneficial effects and untreated also it leads to vitreous haemorrhage and traction retinal detachment. The Eales' disease study (EDS) is still an on-going project and recruitment of the patients is continuing. Over another year we hope to have a larger number of patients, accumulate enough data and cover a longer follow-up period to substantiate these preliminary findings.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app